Reasons for the Termination of Interleukin-17 Inhibitor Medications in the Treatment of Plaque Psoriasis: A Real-World Retrospective Study

Abstract

Keywords

psoriasis interleukin-17 inhibitor real-world experience discontinuation

Get full access to this article

View all access options for this article.

References

Di Meglio

Villanova

Nestle

. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8):a015354. doi:10.1101/cshperspect.a015354

25085957

Gordon

KB.

Blauvelt

Papp

et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med Overseas Ed. 2016;375(4):345-356.doi:10.1056/NEJMoa1512711

Langley

RG.

Elewski

BE.

Lebwohl

et al. Secukinumab in plaque psoriasis — results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338.doi:10.1056/NEJMoa1314258

25007392

Lebwohl

Strober

Menter

et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med Overseas Ed. 2015;373(14):1318-1328.doi:10.1056/NEJMoa1503824

26422722

Ward

Maliyar

Gooderham

. A case report of recalcitrant aphthous ulcers in two patients treated with interleukin-17 inhibitors. SAGE Open Med Case Rep. 2021;9(3):2050313X2110349.doi:10.1177/2050313X211034925

34504710